(2021) reported that CXCR4-expressing CAFs promoted migration and drug resistance in Mycosis Fungoides models, and that the CXCR4 antagonist plerixafor (AMD3100) enhanced apoptosis and reduced motility of neoplastic T cells in vitro (87, 88); these findings support the concept that impairing the CXCL12/CXCR4 axis may have direct anti-tumor effects beyond its established role in stem cell mobilization (89). This evidence concerns the gene CXCL12 and mycosis fungoides.